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CASE REPORT
Emery-Dreifuss muscular dystrophy (EDMD) is a
rare disorder characterized by the clinical triad of
early-onset contractures, progressive weakness in
humeroperoneal muscles, and cardiomyopathy
with conduction block.1 In 1994, Bione et al2 first
reported the X-linked heredity and mapped the
locus to Xp28, which encodes a 34 kD nuclear
membrane protein designated “emerin”. The nu-
clear lamin A/C (LMNA) gene was identified to
be responsible for autosomal dominant EDMD
(AD-EDMD) in 1999.3 Subsequently, different
mutations in the LMNA gene were confirmed to
cause AD and autosomal recessive EDMD in
2000.4 Mutations in LMNA are now known to be
responsible for AD-EDMD, limb-girdle muscular
dystrophy 1B (LGMD1B), dilated cardiomyopa-
thy with conduction system disease (DCM-CD),
Dunningan-type familial partial lipodystrophy,
one recessive axonal form of Charcot-Marie-
Tooth neuropathy, mandibuloacral dysplasia, and
Hutchinson-Gilford progeria; even atypical Werner’s
syndrome, restrictive dermopathy, and metabolic
syndrome are thought to be associated with LMNA
gene mutation.4–7
In this report, we describe the diagnosis of
AD-EDMD in a mother and two daughters based
on the family history, clinical manifestations, and
pathologic findings. Due to the wide clinical spec-
trum, significant intrafamilial variability of severity,
and the need for hereditary consultation, we used
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mutation analysis to detect LMNA gene mutation
in these three clinically diagnosed AD-EDMD
patients and in other family members.
Case Reports
Case 1
An 18-year-old girl had suffered from progressive
muscle weakness since early childhood. She com-
plained of occasional palpitation, easy dizziness,
and mild chest discomfort. Physical and neuro-
logic examinations showed intact, symmetric facial
expression, complete eyelash burying, limited neck
flexion, waddling gait, shoulder and pelvic girdle
muscular atrophy and weakness, and joint con-
tracture over elbow and ankle joints. No tongue
fasciculation, calf muscle hypertrophy, or myoto-
nia was noted. Laboratory tests showed mildly
elevated creatine kinase (CK) at 549 IU/L (normal,
< 174). Nerve conduction velocity was within nor-
mal limits and electromyogram was indicative of
myopathy. A muscle biopsy was then taken over
the left biceps brachii muscle, and showed myo-
pathic change with moderate variation in fiber size,
internal nuclei, occasional necrotic and regener-
ating fibers, and focal connective tissue prolifera-
tion (Figure 1A). Based on the above findings,
EDMD was suspected. Further cardiac surveys
were arranged. Twenty-four-hour Holter electro-
cardiogram (ECG) showed frequent atrial pre-
mature contraction and intermittent first degree
atrioventricular (AV) block; cardiac echo demon-
strated fair systolic function but mild mitral regur-
gitation. No obvious progression was noted and
cardiac function was still fair during 6 years of
follow-up.
Case 2
A 20-year-old young woman, the elder sister of
the proband, visited our hospital due to general-
ized muscle weakness and limited neck flexion.
Serum CK was mildly elevated at 676 IU/L and
muscle biopsy showed marked variation in fiber
size, internal nuclei, and occasional necrotic fibers
(Figure 1B). Twenty-four-hour Holter ECG showed
a markedly prolonged PR interval with paroxysmal
atrial fibrillation; cardiac echo demonstrated fair
systolic function but mild mitral regurgitation. In
the following 2 years, dizziness became more fre-
quent and she complained of exertional dyspnea.
Follow-up 24-hour Holter ECG demonstrated atrial
fibrillation combined with complete AV block. A
rate-responsive single chambered ventricular pace-
maker (Medtronic Sigma SSR 303, Minneapolis,
MN, USA) was implanted in May 2004. Postop-
eratively, 24-hour Holter ECG showed atrial fib-
rillation with ventricular pacing rhythm, and
clinical symptoms including frequent dizziness
and exertional dyspnea were much improved.
Case 3
A 43-year-old woman, the mother of the above
two sisters, was brought to our hospital due to 
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A BFigure 1. Muscle biopsies (M. biceps brachii) of (A) case 1 and 
(B) case 2 demonstrate myopathic changes with variation in 
fiber size, internal nuclei (arrowheads), occasional necrotic fibers
(arrow), and regenerating fibers (star) (hematoxylin & 
eosin, 200×).
a 20-year history of Gowers’ sign and exercise 
intolerance. Twenty-four-hour Holter ECG showed
frequent ventricular premature contraction. Cardiac
echo showed dilated left atrium and left ventricle
with mild mitral regurgitation. Left ventricular
systolic and diastolic functions were normal. She
refused muscle biopsy and was then lost to follow-
up at our outpatient department. Two years later,
she was sent to our emergency room due to sud-
den loss of consciousness with apnea. Junctional
bradycardia with intermittent bigeminal ventric-
ular premature contraction was also noted. Brain
computed tomography showed an infarction-like
lesion over the pons. During hospitalization, he-
modynamically unstable ventricular tachycardia
and ventricular fibrillation developed requiring
electrical cardioversion to resuscitate. She died due
to hypoxic ischemic encephalopathy with heart
and respiratory failure.
Methods
Peripheral blood samples were collected for muta-
tion analysis from these three symptomatic patients
and four other asymptomatic family members
after approval was obtained from the Human
Experiment and Ethics Committee of Kaohsiung
Medical University Hospital. Genomic deoxyribo-
nucleic acid (DNA) was isolated from peripheral
blood mononuclear cells using the Puregene
DNA Isolation Kit (Gentra Systems, Minneapolis,
MN, USA) according to the manufacturer’s instruc-
tions. Polymerase chain reaction (PCR) was per-
formed using specific primer sets for each of the
12 exons of LMNA. The primer sequences are listed
in the Table. Single-strand conformation polymor-
phism analysis of the PCR products was performed
using the GenePhor DNA Separation System and
GeneGel Excel 12.5/24 Kit (Amersham Biosciences
Co., Tokyo, Japan) under each of three different
temperatures of 5°C, 10°C, and 15°C. The aber-
rant PCR products were purified by solid-phase
extraction and bidirectionally sequenced with the
BigDye Terminator Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA) according to the
manufacturer’s instructions. Sequencing reactions
were separated using an ABI 3100 genetic analyzer.
The T6293G mutation of LMNA introduces a new
HpaII restriction site. Genomic DNAs from the pa-
tients and normal individuals were amplified using
the primers 5′-GCTTGGGACTCTGGGGAGA-3′
and 5′-ATGGCTCTGCCTTTAACAATCC-3′ under
the following cycling conditions: 95°C for 3
minutes; 40 cycles of 95°C for 30 seconds, 58°C
for 1 minute, 72°C for 1 minute, followed by
72°C for 5 minutes. The PCR products were 
digested with HpaII (New England Biolabs,
Beverly, MA, USA) and analyzed by agarose gel
electrophoresis.
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Table. LMNA primer sets
Exon Sense primer Antisense primer
1 ACTCCGAGCAGTTCTTGTCC CCTCTCCACTCCCCGCCA
2 CCTTCTCTAAATCTACTCTCCC GGAGGGCCTAGGTAGAAGAGT
3 CCTCTCAGCTTCCTTCAAGTTC CCAGCCCAAGTCTGTCATC
4 GCCTCCCAGGAACTCCTTCTG GTAAGGGTAGGGCTGCCAAG
5 CTGTAGCAGTGATGCCCAACT ATCCCTCTCCTCCTCAGGAA
6 CCTTGGGAGCTCACCAAAC GCCAGAGGACACTGCCAGC
7 GGCAACTGGCCTTGACTAGA CATCCTTCTGTCTTGCCACT
8 CCAAGAGCCTGGGTGAGCCTC GACACTTACCCCAGCGCTCC
9 GGAGCGCTGGGGTAAGTGTC CTCGTCCAGCAAGCAGCCAG
10 AGTTGCAGGTGGTCAGTGG TGGGTTCCCTGTTCAAGGTA
11 TTGGGCCTGAGTGGTCAGTC TGCAAGGCCACCTCGTCCTA
12 GTTGTTCACACCTCTCTCCTCTG CAGATGTGGAGTTTCCTGGAA
Results and Discussion
PCR amplification and direct sequencing (Figure 2)
revealed a novel mutation in codon 520 in exon 9
of the LMNA gene, resulting in a substitution of
tryptophan (W) by glycine (G) (missense muta-
tion) in all three patients (II-1, III-1, III-2). These
patients were all heterozygous for the W520G
mutation. Restriction endonuclease analysis of the
W520G mutation showed that HpaII treatment
yielded two fragments, 274 bp and 138 bp, of the
W520G mutant gene and an undigested 412 bp
fragment of the normal gene (Figure 3). Restriction
endonuclease analysis confirmed the mutation
and showed that the four asymptomatic relatives
(II-2, 3, 4, 5) and 200 unrelated normal individuals
did not bear this mutation. Based on molecular
analyses and clinical presentations, AD-EDMD
was diagnosed in these three family members.
The LMNA gene encodes two different proteins,
lamins A/C, produced by alternative splicing.
Lamins A/C are components of the nuclear enve-
lope and expressed in a wide range of tissues, in-
cluding adult heart and skeletal muscle. There are
many theories regarding the effects of LMNA, but
the real mechanism by which LMNA gene muta-
tions cause EDMD and cardiomyopathy is still un-
certain.4,8 More than 70 nucleotide substitutions,
predominantly missense mutations, have been
reported in the LMNA gene, among which 37-point
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Figure 2. Pedigree and partial nucleotide sequence
of LMNA gene show the heterozygous T to G 
mutation at nucleotide position 520 in patients
II-1, III-1 and III-2. This change is absent in 
normal control.
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274 bp
138 bp
II-1
412 bp
Figure 3. Restriction endonuclease analysis of the W520G
mutation: the size of the PCR product is 412 bp; HpaII treat-
ment yielded two fragments, 274 bp and 138 bp, of the
W520G mutant gene and an undigested 412 bp fragment
of the normal gene.
mutations are responsible for AD-EDMD. W520S
(TGGTCG) was previously detected by Bonne
et al,9 but W520G is a novel finding. The correla-
tion between the phenotype and type or localiza-
tion of the mutations within the gene remains
unclear. Vytopil et al10 indicated that mutation
spanning only a few amino acids of evolutionary
highly conserved regions results in phenotypes
with strikingly different symptoms and varying
severity. These studies have demonstrated a high
proportion of de novo mutations and marked inter-
and intrafamilial variabilities in the clinical expres-
sion of LMNA mutations. The broad spectrum of
both LMNA mutations and of clinical expression
should prompt screening for LMNA in familial
and sporadic cases of both EDMD and dilated
cardiomyopathy associated with conduction sys-
tem disease.9
Based on previous literature, nearly half of
EDMD patients died suddenly and the outlook
seemed improved with pacemaker implantation.11
But other studies have shown that the risk of sud-
den death in EDMD patients, even those without
manifest cardiac abnormalities, may be unrelated
to heart failure and unresponsive to pacemaker
therapy.12,13 These findings show the importance
of regular cardiac evaluation and illustrate the
need for further study of the mechanism of sud-
den death. Further, the indication for implantable
cardioverter-defibrillator use thus becomes a new
important question.14 Although the risk of sud-
den death still exists, the elder sister in this family
received pacemaker implantation, which substan-
tially improved her clinical symptoms and life
quality. However, further electrophysiologic exami-
nation and long-term follow-up are necessary.
In conclusion, this is the first report of a novel
W520G mutation in Taiwanese patients with AD-
EDMD. The findings suggest the need for wider
screening of asymptomatic family members of spo-
radic cases. Early intervention for conduction block
is crucial to identify cases and improve life quality.
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